Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Down 20.0% in June

Dermata Therapeutics, Inc. (NASDAQ:DRMA) was the target of a significant decline in short interest in June. As of June 15th, there was short interest totalling 20,400 shares, a decline of 20.0% from the May 31st total of 25,500 shares. Based on an average trading volume of 31,300 shares, the short-interest ratio is currently 0.7 days. Currently, 4.9% of the shares of the stock are short sold.

Dermata Therapeutics Stock Up 2.6 %

DRMA stock traded up $0.06 during midday trading on Friday, hitting $2.39. The company’s stock had a trading volume of 44,404 shares, compared to its average volume of 58,908. Dermata Therapeutics has a 12 month low of $2.10 and a 12 month high of $26.55. The company has a 50 day moving average of $3.89 and a two-hundred day moving average of $5.93. The firm has a market capitalization of $1.05 million, a price-to-earnings ratio of -0.09 and a beta of 0.83.

Dermata Therapeutics (NASDAQ:DRMA) last issued its earnings results on Wednesday, May 15th. The company reported ($7.05) earnings per share for the quarter.

Institutional Trading of Dermata Therapeutics

An institutional investor recently raised its position in Dermata Therapeutics stock. Acadian Asset Management LLC boosted its stake in shares of Dermata Therapeutics, Inc. (NASDAQ:DRMA) by 34.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 75,538 shares of the company’s stock after acquiring an additional 19,253 shares during the quarter. Acadian Asset Management LLC owned about 2.37% of Dermata Therapeutics worth $79,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.67% of the company’s stock.

Dermata Therapeutics Company Profile

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.